Geode Capital Management LLC Grows Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Geode Capital Management LLC boosted its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 0.1% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,218,424 shares of the medical research company’s stock after buying an additional 1,631 shares during the quarter. Geode Capital Management LLC owned 2.38% of Charles River Laboratories International worth $239,179,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in CRL. Oregon Public Employees Retirement Fund lifted its stake in Charles River Laboratories International by 1.0% in the second quarter. Oregon Public Employees Retirement Fund now owns 4,424 shares of the medical research company’s stock worth $914,000 after purchasing an additional 45 shares during the last quarter. Empirical Finance LLC raised its holdings in shares of Charles River Laboratories International by 4.2% in the third quarter. Empirical Finance LLC now owns 1,310 shares of the medical research company’s stock worth $258,000 after buying an additional 53 shares during the period. American Trust boosted its holdings in Charles River Laboratories International by 5.9% during the 2nd quarter. American Trust now owns 976 shares of the medical research company’s stock valued at $202,000 after acquiring an additional 54 shares during the period. Tortoise Investment Management LLC increased its stake in Charles River Laboratories International by 77.0% in the second quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock worth $27,000 after purchasing an additional 57 shares during the period. Finally, OLD National Bancorp IN lifted its position in shares of Charles River Laboratories International by 3.1% during the third quarter. OLD National Bancorp IN now owns 1,988 shares of the medical research company’s stock worth $392,000 after purchasing an additional 59 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Insiders Place Their Bets

In related news, Director Richard F. Wallman sold 6,621 shares of the firm’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the transaction, the director now owns 12,386 shares in the company, valued at $2,676,862.32. This trade represents a 34.83 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 1.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Evercore ISI raised their price target on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research note on Thursday, November 7th. CLSA lowered Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target for the company. in a report on Monday, November 18th. Redburn Atlantic started coverage on Charles River Laboratories International in a research report on Monday, October 14th. They set a “sell” rating and a $151.00 target price for the company. StockNews.com lowered Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Thursday, November 7th. Finally, UBS Group upped their price objective on shares of Charles River Laboratories International from $240.00 to $250.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Three analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have issued a buy rating to the stock. According to MarketBeat, Charles River Laboratories International presently has an average rating of “Hold” and a consensus target price of $214.00.

Charles River Laboratories International Stock Down 2.0 %

Shares of CRL stock opened at $190.46 on Friday. The stock’s fifty day moving average price is $194.35 and its 200 day moving average price is $203.02. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14. Charles River Laboratories International, Inc. has a 1-year low of $176.48 and a 1-year high of $275.00. The company has a market cap of $9.74 billion, a price-to-earnings ratio of 23.84, a price-to-earnings-growth ratio of 5.00 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.43 by $0.16. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The company’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.72 earnings per share. On average, research analysts expect that Charles River Laboratories International, Inc. will post 10.18 earnings per share for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).